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ABSTRACT
Aminoglycosides are of major importance in treating Pseudomonas aeruginosa pneumonia (PAP).
However, their efﬁcacy may be compromised by low-level resistance caused by the inducible MexXY
multidrug efﬂux pump. In the present study, the impact of the MexXY efﬂux pump was investigated
in vivo in an experimental model of PAP in rabbits treated with intravenous tobramycin. Three strains
were used to induce PAP in rabbits: PAO1 (wild-type strain; MIC 1 mg ⁄L), mutant 11B (mexX::Tn501;
no expression of MexXY; MIC 0.5 mg ⁄L) and mutant MutGR1 (MexZ null; constitutive expression of
MexXY; MIC 2 mg ⁄L). Five hours after inoculation, treatment with tobramycin (10 mg ⁄kg) was
implemented (peak serum concentration 30 mg ⁄L). The animals were killed humanely 48 h after
inoculation, and the residual pulmonary bacterial concentration was determined. Selection of bacteria
expressing MexXY was determined by plating lung homogenates on agar plates containing antibiotic.
Mean bacterial counts (log10 CFU ⁄g) for treated vs. untreated rabbits were 6.26 and 8.13 (p < 0.0001),
6.00 and 8.38 (p < 0.001), and 7.25 and 8.79 (p 0.04) for PAO1, 11B and MutGR1, respectively, with an
overall mortality rate of 0% vs. 8.9% (p < 0.01). MexXY-overexpressing bacteria were recovered from
three (21%) treated rabbits. The Cmax ⁄MIC ratio was the parameter that was best associated with
tobramycin efﬁcacy. The bacteria overexpressing MexXY, recovered from lung, occurred with a
Cmax ⁄MIC window of 19–26. It was concluded that the experimental PAP model highlights poor
tobramycin bacteriological efﬁcacy in vivo, contrasting with survival gain, and that the contribution of
the MexXY system to this low level of tobramycin efﬁcacy is modest. Finally, this model appears to be
suitable for the investigation of new anti-pseudomonal therapeutic strategies.
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INTRODUCTION
While aminoglycosides are the cornerstone anti-
biotics for the treatment of Pseudomonas aeruginosa
lung infections, either for ventilator-associated
pneumonia or for patients with cystic ﬁbrosis,
their clinical efﬁcacy may be compromised in vivo,
even though in-vitro assays predict good antimi-
crobial activity [1]. Among known mechanisms of
resistance in P. aeruginosa, the polyspeciﬁc efﬂux
system MexXY (also known as AmrAB), which
belongs to the RND (resistance ⁄nodulation ⁄ cell
division) family of transporters, is thought to play
a key role in the resistance of P. aeruginosa to
aminoglycosides [2]. Expression of the mexXY
operon is regulated negatively by the product of
the upstream putative repressor gene mexZ [2–4].
Overproduction of the MexXY efﬂux pump is
inducible, in part, by its substrate antibiotics,
including aminoglycosides, macrolides and tetra-
cyclines (but not ﬂuoroquinolones, chloramphen-
icol or b-lactams), thereby allowing P. aeruginosa
to adapt rapidly to inhibitory concentrations of
these antibiotics [5,6]. This so-called adaptive
resistance [7,8], generally considered to be low-
level, disappears when the organism is no longer
in contact with these antibiotics. MexXY proteins
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may also be overproduced constitutively as a
result of mutations occurring inside or outside the
mexZ gene, or inside unknown additional genes
involved in the regulation of MexXY expression
[2,4]. Overexpression of the MexXY system in
strain PAO1 (either by adaptive resistance or
following a mutational event) leads to a two- to
eight-fold increase in in-vitro MICs of aminogly-
cosides and ﬂuoroquinolones compared with
those for the wild-type parental strain.
While data are accumulating on the occurrence
of MexXY-overproducing strains in the clinical
setting [2,9,10], little is known about the possible
implications of this system for the emergence of
isolates with reduced susceptibility to aminogly-
cosides, and the resulting consequences for the
efﬁcacy of aminoglycoside treatment. In the pre-
sent study, MexXY overproduction was explored
in an experimental model of P. aeruginosa pneu-
monia in rabbits, which then received treatment
with intravenous tobramycin in a regimen similar
to that used to treat humans. The impact of
overexpression of the MexXY system on tobra-
mycin efﬁcacy in this pneumonia model was also
evaluated.
MATERIALS AND METHODS
Bacterial strains, growth conditions and antibiotics
P. aeruginosa PAO1 was used as the wild-type reference strain.
Mutant 11B is a mexX::Tn501 insertion derivative of PAO1
showing hyper-susceptibility to aminoglycosides, erythromy-
cin and tetracyclines [3]. Mutant MutGR1 is another derivative
of PAO1, and hyper-produces protein MexY constitutively as a
result of a nucleotide substitution (CﬁT) at position 307 in the
repressor gene mexZ [2]. Bacteria were cultured at 37C,
either in Mueller–Hinton broth with adjusted concentrations
of Ca2+ and Mg2+ (MHB; Difco Laboratories, Elancourt,
France) or on Mueller–Hinton agar plates (MHA; bioMe´rieux,
Marcy l’Etoile, France). When necessary, selective growth
media were made by addition of both gentamicin and
ciproﬂoxacin, at concentrations of 2 mg ⁄L and 0.125 mg ⁄L,
respectively.
In-vitro susceptibility testing
Drug MICs were determined by the standard agar dilution
method recommended by the Comite´ de l’Antibiogramme de
la Socie´te´ Franc¸aise de Microbiologie [11]. The antibiogram
of wild-type strain PAO1 displays apparent antagonism
between ciproﬂoxacin and aminoglycoside disks, as a result
of in-vitro adaptive resistance induced by the aminoglyco-
side, leading to decreased susceptibility to ciproﬂoxacin.
The antibiogram of PAO1 overexpressing MexXY efﬂux is
similar to that of strain MutGR1, with decreased suscepti-
bility to all aminoglycosides, ciproﬂoxacin and cefepime, and
loss of antagonism between aminoglycosides and cipro-
ﬂoxacin. The antibiogram of strain 11B shows increased
susceptibility to aminoglycosides, ciproﬂoxacin and cefepime,
and no antagonism between aminoglycosides and cipro-
ﬂoxacin, because of the absence of an efﬁcient MexXY system
[2,3,12].
Preparation of the inoculum
Before each animal experiment, one aliquot of the selected
strain was inoculated into MHB, cultured on agar plates, and
then incubated for 24 h at 37C. Three colonies were then
taken, incubated in 10 mL of MHB for 6 h at 37C, and then
cultured on an agar plate for 18 h at 37C. This culture was
then diluted in physiological saline to obtain a ﬁnal concen-
tration of 9.5 log10 CFU ⁄mL. No adjuvant was used. These
concentrations were determined initially by OD measurements
with reference to a standard curve, and were then conﬁrmed
by using successive dilution cultures.
Experimental P. aeruginosa pneumonia in rabbits
Male New Zealand White immunocompetent rabbits (body
weight 2.5–3.2 kg) were obtained from CEGAV (Saint Mars
d’Egrenne, France), placed in individual cages, and provided
with food and water ad libitum. Installation of central venous
catheters and production of pneumonia were as described
previously [13,14]. In brief, 24 h after jugular catheterisation,
bacterial pneumonia was induced by endobronchial challenge
with 0.5 mL of saline containing 9.5 log10 CFU ⁄mL. Treatment
was by infusion, started 5 h after bacterial challenge, and
lasted for 2 days. Tobramycin was delivered through the ﬁrst
central venous catheter, with changing infusion rates, deliv-
ered by a computer-controlled electric pump, in order to
simulate the tobramycin kinetics observed in human serum
following a dose of 10 mg ⁄ kg given intravenously once-daily
(concentration at the end of the infusion, Cmax 30 mg ⁄L)
[15,16].
Pharmacokinetic analysis
For each animal, antibiotic serum concentrations were deter-
mined on iterative blood samples, obtained through the
second central catheter. Tobramycin concentrations were
determined by a disk plate bioassay with antibiotic medium
II (Difco) and Bacillus subtilis ATCC 9466 as the indicator
organism (limit of detection 0.1 mg ⁄L). Standard curves were
established with antibiotic solutions (0.5–7 mg ⁄L) in serum.
The linearity of the standard curves used for disk plate
bioassays was ‡ 0.97 (r2). Serum samples were diluted in serum
where necessary to ensure that their concentrations were
within the range of those on the standard curve. The standards
were assayed for each experiment, and serum concentrations
were assayed in duplicate. The between-day and within-day
coefﬁcients of variation for replicates were 10.7% and 11.7%,
respectively. The level of plasma protein binding was consid-
ered to be null [17].
Evaluation of infection
The rabbits were anaesthetised and killed humanely 48 h after
inoculation. Twenty-three animals were used as controls
without treatment (13, six and four animals for strains PAO1,
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11B and MutGR1, respectively), and 46 animals were treated
with intravenous tobramycin (18, 11 and nine animals infected
with strains PAO1, 11B and MutGR1, respectively). The spleen
and both lungs of each rabbit were weighed and homogenised
in sterile water. Bacteria were enumerated by serial dilution on
MHA, followed by incubation of the plates for 24 h at 37C.
Bacterial concentrations in each lung and in the spleen were
determined after adjusting for weight. For each rabbit, the
mean pulmonary bacterial concentration was calculated using
the bacterial concentration in each lung (expressed as CFU ⁄ g).
In the group of rabbits infected with strain PAO1, bacteria
expressing MexXY efﬂux were detected by plating the crude
homogenate tissue and ten-fold dilutions on MHA made
selective by the addition of gentamicin and ciproﬂoxacin as
described above, followed by incubation for 72 h at 37C. An
antibiogram was determined for any colonies recovered on
this selective medium to determine whether the MexXY
phenotype was present (see above). Colonies overexpressing
MexXY efﬂux were then tested for reversion by performing a
new antibiogram after seven subcultures on antibiotic-free
MHA.
Pharmacodynamic analysis
The following parameters related to MIC were calculated from
the individual pharmacokinetics of each treated animal:
Cmax ⁄MIC; area under the curve of serum concentration vs.
time (0–24 h) AUC0)24 ⁄MIC; and time of concentration above
MIC (T > MIC, expressed as a percentage). These parameters
were termed pharmacodynamic–pharmacokinetic parameters.
Statistical analysis
Results were expressed as means ± SD. Quantitative variables
were compared to analysis of variance and eventually com-
pleted by a post-hoc analysis using the Bonferroni test.
Proportions percentages were compared using the Fisher exact
test. The quantitative relationship between antimicrobial efﬁc-
acy and each of the pharmacodynamic–pharmacokinetic
parameters was determined by using an Emax model (Hill
formula). Kaplan–Meier methodology was used for the survi-
val study, using the log-rank test, with multivariate analysis
performed with a Cox model. p < 0.05 was considered
signiﬁcant.
RESULTS AND DISCUSSION
Experimental P. aeruginosa pneumonia in
rabbits
The MICs for the three strains used to infect the
rabbits are summarised in Table 1. All strains
were susceptible to tobramycin (MIC £ 4 mg ⁄L)
and ciproﬂoxacin (MIC £ 1 mg ⁄L). Only strain
MutGR1 was resistant to gentamicin (MIC >
8 mg ⁄L). When the serum concentration vs. time
curve of tobramycin observed in rabbits was
superimposed on human pharmacokinetic data
[16], there was no difference between the rabbit
groups, as deﬁned by strains, with respect to
tobramycin exposure, as measured by Cmax and
AUC0)24.
Residual bacterial concentrations in lungs for
treated vs. control rabbits were 6.26 ± 0.96
log10 CFU ⁄g (n = 18) vs. 8.13 ± 0.90 log10 CFU ⁄g
(n = 13), 6.00 ± 1.05 log10 CFU ⁄ g (n = 10) vs.
8.38 ± 1.06 log10 CFU ⁄ g (n = 6), and 7.25 ±
1.24 log10 CFU ⁄ g (n = 9) vs. 8.79 ± 0.62 log10 C-
FU ⁄ g (n = 4), for rabbits infected with strains
PAO1, 11B and MutGR1, respectively (Fig. 1). For
each of the three groups of treated animals, the
standard human-like tobramycin regimen was
effective for pulmonary infection when compared
with controls without treatment (p < 0.05 for
each pair). The bacterial burdens in the animals
receiving antibiotic treatment were similar to
those observed in humans and (e.g.) in cystic
ﬁbrosis patients treated with intravenous
antibiotics [18].
Spleen infection reﬂects bacteraemic events,
and there was no difference, with respect to the
mean bacterial concentration in spleens, between
Table 1. Strains of Pseudomonas aeruginosa used in this
study
Strain
Relevant
properties MexXY efﬂux
MIC (mg ⁄L)
Tobramycin Gentamicin Ciproﬂoxacin
PAO1 Wild-type Inducible 1 4 0.125
11B mexX null Non-functional 0.5 0.5 0.125
MutGR1 mexZ null Overexpressed 2 16 0.5
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Fig. 1. Residual bacterial concentrations (log10 CFU ⁄ g) in
(a) lungs and (b) spleen of rabbits infected with Pseudo-
monas aeruginosa strains exhibiting varying expression
levels of the MexXY efﬂux system (see Table 1). Treatment
was for 48 h in a model of a human regimen of intravenous
tobramycin (dashed bars, equivalent to 10 mg ⁄ kg once-
daily in humans) in comparison with untreated controls
(white bars). *Strain MutGR1 < PAO1 and 11B, and all
treated vs. untreated animals, p < 0.05.
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treated and untreated rabbits in any group, as
deﬁned by the infecting strain. Tobramycin treat-
ment did not reduce the spleen infection rate
(72.1% at 48 h).
Overall, 48-h survival was signiﬁcantly greater
for animals receiving tobramycin treatment
(100% for treated rabbits vs. 81.1% for untreated
rabbits; p < 0.01), with no signiﬁcant difference
between groups as deﬁned by the infecting strain.
Bacterial concentrations in the lungs and spleen
were associated signiﬁcantly with mortality in
univariate analysis (risk ratio 1.57, p 0.008, and
risk ratio 9, p < 0.01, respectively); however, in
multivariate analysis, pulmonary bacterial con-
centration was the only parameter associated
signiﬁcantly with mortality (risk ratio 5.8,
p < 0.01). This is consistent with previous clinical
studies highlighting the contrast between poor
antimicrobial efﬁcacy and improved survival
[1,19–21].
In-vivo impact of the MexXY efﬂux system
Colonies were recovered on selective media from
four control rabbits and four treated rabbits
infected with wild-type strain PAO1. All of the
colonies obtained from control rabbits had a wild-
type antibiogram, whereas colonies with the
MexXY phenotype, as deﬁned by antibiogram,
were retrieved from three treated rabbits (P35,
P55 and P74) and had a gentamicin MIC of
16 mg ⁄L. The pulmonary concentrations for these
animals were 4.48, 1.39 and 1.40 log10 CFU ⁄g,
with total residual bacterial concentrations of 7.59,
7.38 and 6.35 log10 CFU ⁄ g lung, respectively
(Fig. 2). The frequency at which resistance ap-
peared in Pseudomonas in treated animals (3 ⁄ 14,
21%) is similar to the ﬁgure of 26% reported
for treated humans [22]. After subcultures on
antibiotic-free media, this MexXY phenotype
appeared to be transient for all nine colonies
recovered from the ﬁrst rabbit (P35), but was
stable for the colonies recovered from the two
other treated rabbits. This suggests an adaptive
resistance phenomenon in rabbit P35, with a
MexXY overexpression rate of c. 10)3, whereas
stable mutational events occurring at a lower
frequency of c. 10)5)10)6 seem to have been
selected in the colonies from rabbits P55 and
P74 [5].
The impact of MexXY overexpression on the
efﬁcacy of tobramycin was assessed by compar-
ing the residual bacterial concentrations in treated
rabbits. Surprisingly, there was no signiﬁcant
difference in terms of residual bacterial concen-
trations between treated rabbits infected with the
mexX-deleted strain 11B and treated rabbits infec-
ted with the wild-type strain PAO1. This suggests
that MexXY efﬂux is of low signiﬁcance and does
not account for the low antimicrobial efﬁcacy of
tobramycin in rabbits infected with strain PAO1
in the present model. This contrasts with previous
in-vitro and ex-vivo studies that have hypothe-
sised that the MexXY efﬂux system could be a
major mechanism involved in in-vivo resistance
to aminoglycosides [2,3,5,23]. However, residual
pulmonary bacterial concentrations in the pre-
sent study were signiﬁcantly higher in treated
rabbits infected with strain MutGR1 than in both
other groups, suggesting that overexpression of
MexXY is responsible for the decreased antimi-
crobial efﬁcacy of tobramycin. Thus, overexpres-
sion of this efﬂux system may be of concern in a
clinical setting with longer aminoglycoside treat-
ment periods where there is a higher risk of
occurrence of resistance and therapeutic failure
[24].
Pharmacodynamic analysis
Exposure to tobramycin was the same for the
three groups (AUC0)24 120 ± 24, 115 ± 15 and
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Fig. 2. Relationship between Cmax ⁄MIC ratio and the
residual bacterial pulmonary concentration (log CFU ⁄ g)
obtained with Pseudomonas-induced pneumonia in rabbits
treated with a 2-day human-like regimen of intravenous
tobramycin. Open squares represent animals in which
overexpression of the MexXY system was detected in
bacteria from the lungs (see text). The black curve
represents the regression line (Emax model, p 0.05).
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106 ± 26 (mg h) ⁄L for animals infected with
strains 11B, MutGR1 and PAO1, respectively).
Following pharmacodynamic analysis, two phar-
macodynamic–pharmacokinetic indices were
poorly, but signiﬁcantly, associated with tobra-
mycin efﬁcacy, as measured by the residual load
of Pseudomonas in lungs, namely Cmax ⁄MIC
(r2 0.25, p < 0.05; Fig. 2) and AUC0)24 ⁄MIC
(r2 0.18, p < 0.05), thereby conﬁrming the concen-
tration-dependent effect of tobramycin. It is of
note that overexpression of MexXY occurred
within the maximal selection window, i.e., be-
tween the Cmax ⁄MIC values of 19 and 27. At
higher values there was a plateau with no further
decrease in bacterial load, which is in agreement
with data published previously [25,26].
Conclusions
In contrast to previous studies performed in the
planktonic ⁄ aerobic phase, in which the tested
strains were all tobramycin-susceptible in vitro,
the model system described in the present study
indicates that the MexXY efﬂux system is of low
signiﬁcance and is not responsible for the poor
antimicrobial activity of tobramycin in rabbits
infectedwith thewild-type PAO1 strain.However,
MexXY overexpression contributes to the increase
in resistance to tobramycin observed in rabbits
infected with strain MutGR1. Thus, other mecha-
nisms of resistance to aminoglycosides must be
involved, and these may have a greater impact in
vivo than the MexXY efﬂux system in P. aeruginosa
infections. Furthermore, although a concentration–
effect relationship was conﬁrmed in the present
study, tobramycin had a relatively low level of
efﬁcacy in reducing the bacterial load in lungs,
although there was a signiﬁcant improvement in
survival, probably associated with limited bacter-
ial dissemination during treatment, as suggested
by the splenic bacterial loads. The pulmonary
bacterial reduction was c. 2 log10 CFU ⁄ g, roughly
inversely proportional to the MIC, which is
consistent with results obtained in other animal
models ofP. aeruginosapneumonia, although these
models did not use regimens similar to those used
in humans [27–30]. The bacterial reduction in lung
tissue is also consistent with observations from
clinical studies [20,31,32].
Many factors could explain the difﬁculty in
eradicating P. aeruginosa strains causing pneu-
monia. Local hypoxia [33–35] and low pH [36]
may partly account forweak antimicrobial activity,
since histopathological examination conﬁrmed the
presence of ischaemic lesions and multiple micro-
abscesses. These lesions are similar to those seen in
humans [37–39]. Tissue concentrations of tobra-
mycin have not been determined because of tech-
nical difﬁculties, but tissue structure alterations
may result in lower tissue concentrations so that
the MIC for the infecting organism is not reached.
In addition, observations of lung sections revealed
that P. aeruginosa formed bronchial plugs and
clusters ⁄microcolonies in both treated and un-
treated animals, and the formation of such bioﬁlms
may explain in-vivo resistance to antibiotics
[34,40,41]. The relatively poor efﬁcacy of human
tobramycin regimens may be explained by
increased bacterial impermeability [42], by modi-
ﬁcation of periplasmic glucans [43], and by meta-
bolic limitation and adaptation [33,44–48], with all
of these factors contributing to increased MICs in
bioﬁlms [49–53], while the different efﬂux-pump
systems, including MexXY, contribute only parti-
ally to classic antibiotic resistance [50]. Thus, the
present results obtained with the model are con-
sistent with existing knowledge [35,40,52,54–56],
and the model seems to be well-suited for inves-
tigations of other anti-pseudomonal therapeutic
strategies.
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